Citi raised the firm’s price target on HCA Healthcare to $357 from $309 and keeps a Buy rating on the shares. After HCA’s Q4 EBITDA “beat by a healthy margin,” the firm raised its target on higher 2024 EBITDA-NCI estimates. While Citi expects pushback on a “frothy valuation,” the analyst continues to believe HCA “can grind higher as momentum carries through.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HCA:
- HCA Healthcare price target raised to $345 from $320 at Truist
- HCA Healthcare price target raised to $322 from $308 at RBC Capital
- HCA Healthcare price target raised to $330 from $280 at Deutsche Bank
- HCA Healthcare price target raised to $354 from $338 at Leerink
- HCA Healthcare price target raised to $330 from $315 at Oppenheimer
